Live Analyst Rating Changes 27161 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robert LeBoyer
NF

Robert LeBoyer

Wall Street Analyst
★★☆☆☆
#2394
on 13Foresight · ranked by our own returns
34%
Success Rate
-5.8%
Average Return
15 of 44 calls profitable · +23.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 34% of Robert LeBoyer's ratings turned a profit when each position was held for 1 year — averaging -5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

90 Buy 0 Hold 0 Sell
Robert's Stock Coverage 43 ratings · 2026-08-24
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
ELDN
Eledon Pharmaceuticals
Aug 14, 2026 BUY Strong Buy
+350.3% avg upside
11 analysts
$10.00
189.81% Upside
-2.5% ·
UNCY
Unicycive Therapeutics
Aug 13, 2026 BUY Strong Buy
+824.9% avg upside
10 analysts
$50.00
788.03% Upside
+0.9% ·
NTRB
Nutriband
Aug 12, 2026 BUY Strong Buy
+221.5% avg upside
1 analyst
$15.00
221.50% Upside
+51.7% ·
NRSN
Neurosense Therapeutics Ltd.
Aug 11, 2026 BUY Strong Buy
+2125.6% avg upside
5 analysts
$9.00
2291.73% Upside
-20.7% ·
NNVC
NanoViricides
Aug 11, 2026 BUY Strong Buy
+332.3% avg upside
3 analysts
$6.00
351.12% Upside
-2.2% ·
GYRE
Gyre Therapeutics
Aug 10, 2026 BUY Strong Buy
+200.5% avg upside
15 analysts
$20.00
189.46% Upside
+2.8% ·
OCGN
Ocugen
Aug 07, 2026 BUY Strong Buy
+568.0% avg upside
17 analysts
$12.00
763.38% Upside
+8.6% ·
GOVX
GeoVax Labs
Jul 29, 2026 BUY Strong Buy
+11904.3% avg upside
5 analysts
$10.00
1448.96% Upside
-7.4% ·
CVKD
Cadrenal Therapeutics, Inc.
Jul 14, 2026 BUY Strong Buy
+1701.3% avg upside
2 analysts
$45.00
2695.05% Upside
-33.5% ·
MAIA
MAIA Biotechnology, Inc.
Jul 09, 2026 BUY Strong Buy
+763.3% avg upside
2 analysts
$14.00
907.11% Upside
-4.8% ·
GLSI
Greenwich LifeSciences
Jun 02, 2026 BUY Strong Buy
+241.8% avg upside
2 analysts
$45.00
169.85% Upside
-31.4% ·
COCP
Cocrystal Pharma
May 27, 2026 BUY Strong Buy
+595.7% avg upside
2 analysts
$10.00
769.63% Upside
-0.9% ·
CRDF
Cardiff Oncology
May 22, 2026 BUY Buy
+1045.0% avg upside
18 analysts
$12.00
1263.52% Upside
-49.4% ·
STLN
Starling Oncology Institute
May 08, 2026 BUY Strong Buy
+9.3% avg upside
7 analysts
$8.00
23.80% Upside
+66.5% ·
TNXP
Tonix Pharma
Mar 16, 2026 BUY Strong Buy
+122.8% avg upside
8 analysts
$37.00
194.84% Upside
-7.4% ·
ZOMDF
Zomedica
Jun 27, 2025 HOLD Buy
+1297.0% avg upside
3 analysts
+140.0% ·
TRAW
Traws Pharma
Feb 24, 2025 HOLD Buy
+5843.4% avg upside
10 analysts
-61.8% ·
PDSB
PDS Biotechnology
Feb 24, 2025 HOLD Strong Buy
+6340.0% avg upside
11 analysts
-48.1% ·
ZVSA
ZyVersa Therapeutics
Jan 21, 2025 HOLD Buy
+116122.8% avg upside
2 analysts
-88.2% ·
GNPX
Genprex
Aug 16, 2022 BUY Strong Buy
+89.8% avg upside
5 analysts
$5.00
26.60% Upside
· ·
LCTX
Lineage Therap
Aug 15, 2022 BUY Strong Buy
+412.9% avg upside
16 analysts
$9.00
733.43% Upside
-8.2% ·
AU:IMU
Imugene
Jun 01, 2022 BUY Strong Buy
+700.0% avg upside
2 analysts
$0.70
758.01% Upside
· ·
AVXL
Anavex Life Sciences
May 14, 2021 BUY Strong Buy
+643.3% avg upside
9 analysts
$19.50
501.93% Upside
-22.5% ·
YTENQ
Yield10 Bioscience
Feb 09, 2021 BUY Hold
+37874900.0% avg upside
6 analysts
$27.00
26999900.08% Upside
· ·
ORMP
Oramed Pharm
Jan 26, 2021 BUY Strong Buy
+299.2% avg upside
7 analysts
$15.00
211.91% Upside
+25.4% ·
CNSY
Cerenome
Jan 25, 2021 BUY Strong Buy
+946.4% avg upside
11 analysts
$8.00
160.49% Upside
· ·
CBUS
Cibus
Jan 24, 2021 BUY Buy
+910.6% avg upside
10 analysts
$14.00
723.57% Upside
· ·
CNSP
CNS Pharmaceuticals
Dec 28, 2020 HOLD Strong Buy
+380.2% avg upside
5 analysts
· ·
OTLK
Outlook Therapeutics
Dec 24, 2020 BUY Buy
+1330.3% avg upside
11 analysts
$6.00
827.07% Upside
· ·
ONCSQ
OncoSec Medical
Nov 12, 2020 BUY Strong Buy
+4699999900.0% avg upside
9 analysts
$8.00
799999899.94% Upside
· ·
BNTC
Benitec Biopharma
Oct 05, 2020 HOLD Strong Buy
+85.5% avg upside
14 analysts
+9.1% ·
JAGX
Jaguar Animal Health
May 28, 2020 BUY Strong Buy
+440.3% avg upside
5 analysts
$5.00
476.28% Upside
· ·
MTVA
MetaVia
Feb 18, 2020 BUY Strong Buy
+1948.6% avg upside
13 analysts
$30.00
1954.87% Upside
· ·
SCYX
SCYNEXIS
Nov 01, 2018 HOLD Strong Buy
+151.6% avg upside
10 analysts
· ·
INDP
Indaptus Therapeutics
Nov 01, 2018 HOLD Buy
+7089.9% avg upside
6 analysts
· ·
VTVT
vTv Therapeutics
Apr 10, 2018 HOLD Strong Buy
+8.0% avg upside
13 analysts
$1.00
97.07% Downside
+110.1% ·
LSTA
Lisata Therapeutics
Feb 02, 2018 HOLD Buy
+735.5% avg upside
11 analysts
· ·
HURA
TuHURA Biosciences
Feb 02, 2018 HOLD Strong Buy
+356.2% avg upside
8 analysts
· ·
AIXC
AIxCrypto Holdings
Feb 02, 2018 HOLD Strong Buy
+882.1% avg upside
7 analysts
· ·
MTNB
Matinas BioPharma
Feb 02, 2018 HOLD Buy
+7106.5% avg upside
7 analysts
· ·
CRBP
Corbus Pharmaceuticals
Feb 02, 2018 HOLD Strong Buy
+238.2% avg upside
20 analysts
· ·
ROSGQ
Rosetta Genomics
Feb 02, 2018 HOLD Hold
+4499900.0% avg upside
4 analysts
· ·
ACAD
ACADIA Pharmaceuticals
Aug 05, 2016 HOLD Strong Buy
+25.1% avg upside
43 analysts
$41.00
38.98% Upside
-15.9% ·
🔒 38 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Robert LeBoyer — Frequently Asked Questions
How accurate are Robert LeBoyer's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Robert's ratings were profitable over a one-year hold, with an average return of -5.8% per rating, or +23.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Robert ranked on 13Foresight?
Robert LeBoyer is currently ranked #2394 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robert cover?
Robert most recently has ratings on ELDN, UNCY, NTRB, NRSN, NNVC, GYRE, OCGN, GOVX, CVKD, MAIA, GLSI, COCP and 31 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.